Prostate Cancer

Dendreon presents new Provenge data analyses at Prostate Cancer Foundation Scientific Retreat

Published in Cancer Weekly, November 21st, 2006

Dendreon Corporation (DNDN) announced that Eric J. Small, MD, professor of medicine and urology at the University of California, San Francisco, presented new exploratory analyses of the Phase 3 Study (D9901) that further support the results observed with the company's investigational active cellular immunotherapy Provenge (sipuleucel-T) in men with advanced androgen-independent (hormone refractory) prostate cancer.

These data were presented at the Prostate Cancer Foundation's 13th Annual Scientific Retreat in Scottsdale, Arizona. The company plans to complete the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) prior to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-11-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry